Vedana Therapeutics
Facts
- HQ
- Seattle, Washington, USA
- Sectors
- Biotechnology Research
- Employees
- 19
- Stage
- Series A
Recent coverage
Front-page news, podcasts and videos about Vedana Therapeutics
Helion’s $465M Series G Values Everett Fusion Firm Above $15B, Tops Seattle-Area 2Q VC Deals
Everett fusion-energy company Helion led greater Seattle-area 2Q venture capital deals with a $465 million Series G that valued it above $15 billion, making up nearly one-third of the region’s $1.5 billion in 2Q funding amid a year-over-year decline from $2.3 billion in 2Q 2025.
Vedana Therapeutics Raises $46M Series A Led by Westlake BioPartners and Canaan Partners for Migraine Therapy Development
Vedana Therapeutics, a Seattle-based biotech company focused on migraine prevention therapies, raised $46 million in a Series A funding round. The round was led by Westlake BioPartners and Canaan Partners, with participation from Dawn Biopharma.
Seattle Biotech Vedana Therapeutics Raises $46 Million to Develop Injectable Migraine Treatments
Seattle biotech Vedana Therapeutics raised $46 million in funding to develop injectable migraine treatments and plans to start Phase 1 trials next year under CEO Anurag Agarwal. The company has launched out of stealth mode to pursue its migraine therapy development.
People
-
Anurag Agarwal Executive, CEO, Co-Founder and CEO
